成骨生长肽

成骨生长肽 (OGP)在体内能增加骨形成 ,增加骨小梁密度 ,促进骨折愈合。其体外作用是促进骨髓基质细胞有丝分裂原和碱性磷酸酶活性 ,并促使基质矿化。此外 ,OGP可促进造血 ,包括促进骨髓移植物的成活 ,对放、化疗后骨髓的抑制有造血再生作用。     

壳聚糖微球包裹幽门螺杆菌全菌蛋白抗原的制备及体外释放性能

背景：包裹幽门螺杆菌全菌蛋白抗原的研究仍处于探索阶段,有关壳聚糖微球包裹幽门螺杆菌全菌蛋白抗原的制备工艺及体外释放性能的文献甚少。 目的：探讨幽门螺杆菌全菌蛋白抗原壳聚糖微球的制备工艺及体外释放特性。 方法：采用沉淀法制备壳聚糖微球,筛选最佳制备工艺及配比、包裹时间,并在电镜下观察微球的形态和粒径。采用壳聚糖微球包裹幽门螺杆菌全菌蛋白抗原,BCA法测定幽门螺杆菌全菌蛋白抗原微球的包裹率、包裹量及体外释放率。 结果与结论：终体积分数为1%的冰醋酸、硫酸钠为交联剂、pH 5.0、滴加交联剂时不粉碎处理为壳聚糖微球最佳制备工艺,电镜观察显示微球表面光滑、形态圆整,具有良好的分散性,多数微球粒径为1.0-5.0 μm。幽门螺杆菌全菌蛋白抗原微球的包裹率为80.4%,包裹量为16.4%,48 h总释放率为19.4%,幽门螺杆菌全菌蛋白抗原微球整体呈缓慢释放状态。结果证实,实验制备的壳聚糖微球对幽门螺样菌全菌蛋白抗原具有良好的包裹率和包裹量,幽门螺杆菌全菌蛋白抗原微球整体呈缓慢释放状态。中国组织工程研究杂志出版内容重点：生物材料;骨生物材料; 口腔生物材料; 纳米材料; 缓释材料; 材料相容性;组织工程      

海藻酸钠微球的制备及应用研究进展

海藻酸钠(SA)是从褐藻类海带中提取的一种天然高分子材料,具备出色的生物相容性、无毒性、生物降解性以及丰富的储存量。海藻酸钠凝胶形成的条件温和,可有效避免活性物质的失活。经过多种制备方法,海藻酸钠微球被广泛用于生物材料和组织工程等领域。本文综述了制备海藻酸钠微球的常见方法,包括挤出法、乳化法、静电喷射法、喷雾干燥法和同轴气流法,并探讨了它在骨修复、止血以及药物递送等生物医学领域的应用。     

人同种异体骨载异烟肼-壳聚糖缓释微球的制备和体内外释药特性☆

背景：壳聚糖微球具有良好的生物相容性及抗菌活性,被广泛地运用于各种药物缓释系统中。 目的：制备人同种异体骨载异烟肼-壳聚糖微球,并分析其体内释药性能。 方法：用喷雾干燥法制备异烟肼-壳聚糖微球,进行体外45 d的药物释放实验。将单独装载异烟肼的异体骨块(对照组)和装载异烟肼-壳聚糖微球的异体骨块(实验组)分别植入家兔两侧髂骨,采用高效液相色谱法检测药物体内释放情况。 结果与结论：异烟肼-壳聚糖微球外观呈圆形、表面光滑、分散良好;平均粒径(3.33±0.9) μm,载药率(16.25±1.24)%。体外药物释放实验显示无突释现象,24 h释放20%左右,45 d释放76%,释放曲线较平缓,释放稳定;数学模型拟合符合Ritger-Peppas模型。实验组异烟肼浓度在前28 d内缓慢升高,其后缓慢下降,持续56 d以上,浓度38.50~155.75 µg/g;对照组异烟肼浓度在1周左右达高峰,为1982.5 µg/g,21 d后骨块周围药物不能测到。说明异烟肼-壳聚糖缓释微球在体内外均可以缓慢平稳释放异烟肼,且持续时间长。提示人同种异体骨载异烟肼-壳聚糖缓释微球复合体可以作为骨结核病灶清除后的一种置入材料,在提供机械支持的同时进行长时间的局部化疗。     

壳聚糖微球复合丝素基硫酸钙骨水泥的理化特性

背景：脊柱成形和脊柱后凸成形治疗中采用的硫酸钙骨水泥理化性质好,对人体无毒性作用,同时具有降解性能,但单独使用降解较快。 目的：研制具有载药缓释功能的壳聚糖微球丝素基硫酸钙骨水泥。 方法：采用三聚磷酸钠乳化交联法制备壳聚糖微球。采用浓度分别为3%,6%,9%的丝素溶液与CaSO₄•0.5H₂O混合,通过万能力学试验机确定骨水泥力学性能最佳时的丝素浓度,在此浓度下,按壳聚糖微球占CaSO₄•0.5H₂O的质量比分别为0.5%,1%,5%的比例制备壳聚糖微球丝素基硫酸钙骨水泥,测定其抗压强度,并通过X射线多晶衍射仪及傅里叶红外光谱明确达到最佳抗压强度组的骨水泥成分,电镜观察复合骨水泥中壳聚糖微球的形态。 结果与结论：当丝素溶液浓度为6%,壳聚糖微球含量为0.5%时,复合骨水泥的抗压强度最大,为  (39.17±1.96) MPa,此时复合骨水泥的初凝时间为(12.99±1.63) min,终凝时间为(21.55±0.54) min;骨水泥中主要晶相组成为硫酸钙,傅里叶红外光谱结果证实复合骨水泥中含有丝素及壳聚糖;复合骨水泥中的微球表面稍有皱缩,但球形仍然完整,未见明显破坏,可见在制备复合骨水泥的过程中微球能保持稳定而不被破坏。中国组织工程研究杂志出版内容重点：生物材料;骨生物材料; 口腔生物材料; 纳米材料; 缓释材料; 材料相容性;组织工程全文链接：     

N-乙酰半胱氨酸丝素微球复合磷酸钙骨水泥的制备及表征

BACKGROUND: Calcium phosphate bone cement has been applied to clinical surgery because of its good biocompatibility and osteoconduction. However poor mechanical properties and lack of osteoinductivity limit its wide application. OBJECTIVE: To develop calcium phosphate cement incorporated with N-acetylcysteine (NAC) loaded silk fibroin microspheres (SFM), which is a kind of new injectable bone graft material with slow-release function, and evaluate its physical and chemical properties and cell compatibility. METHODS: Empty SFMs were prepared with emulsion solvent evaporation to absorb NAC solution of different concentrations by NAC-SFM and the concentration of NAC at the maximum drug loading ratio was determined. Then, NAC-SFM was loaded into calcium phosphate bone cement to test the drug release properties in vitro. MC3T3-E1 osteoblasts were cultured on the surface of NAC-SFM calcium phosphate bone cement and cell attachment and growth were observed by scanning electron microscope. Additionally, MC3T3-E1 cells were cultured with three kinds of bone cement extracts (calcium phosphate cement, SFM-calcium phosphate cement, NAC-SFM-calcium phosphate cement, as well as cultured in the α-minimum essential medium containing a volume fraction of 10% fetal bovine serum and 1% penicillin-streptomycin double antibody as the control. MTS assay was used to evaluate cell proliferation. RESULTS AND CONCLUSION: Microspheres in the composite bone cement presented with smooth surface, same size, diffused distribution and no obvious destroy. Thus, the SFM could remain stable in the reaction process of the composite bone cement. The double slow release system which contained silk fibroin microspheres and calcium phosphate bone cement showed a significant decrease in the cumulative release percentage of NAC within the first 24 hours compared with the control group (P < 0.05). In the next 28 days, the release speed of NAC was significantly lower in the NAC-SFM-calcium phosphate cement group than the calcium phosphate cement group (P < 0.05). In addition, different extracts had no significant cytotoxicity to the growth of MC3TC-E1 cells. Thus, the NAC-SFM-calcium phosphate cement has good cytocompatibility, which provide a new insight into the development of bone repair biomaterials. 中国组织工程研究杂志出版内容重点：生物材料;骨生物材料; 口腔生物材料; 纳米材料; 缓释材料; 材料相容性;组织工程     

纳米羟基磷灰石/羧甲基壳聚糖-海藻酸钠复合骨水泥的性能

背景：目前普遍使用的黏合剂对粉碎骨折块进行黏合复位或多或少都存在一些缺陷。 目的：研制具有黏接骨骼作用的生物活性骨水泥。 方法：应用共沉淀法制备纳米羟基磷灰石/羧甲基壳聚糖-海藻酸钠复合材料作为骨水泥的固相粉体,将柠檬酸衍生物配制成溶液作为液相。通过优化实验,从骨水泥的固化时间、抗压强度、抗拉强度、抗稀散性等方面确定最佳配比。 结果与结论：纳米羟基磷灰石/羧甲基壳聚糖-海藻酸钠质量比为65/35,其中羧甲基壳聚糖和海藻酸钠质量比为4∶1时复合成粉体,并按固液比为1.0∶0.5(g∶mL)调拌后形成的骨水泥呈膏状,塑形性和抗稀散性能良好,固化时间12~18 min,抗压强度为(4.5±2.1) MPa。体外黏接猪股骨头抗拉强度在不同室温下无显著性差异无显著性意义(P > 0.05),固化后2 h的抗拉强度达到24 h的94%。骨水泥为多孔状结构,孔径为100~300 μm,纳米羟基磷灰石分布较均匀。提示制备的纳米羟基磷灰石/羧甲基壳聚糖-海藻酸钠复合骨水泥具有良好的生物活性、适当的力学强度以及较好的黏合强度。     

成骨生长肽促进钛表面大鼠成骨细胞的增殖分化

背景：成骨生长肽具有促进多种基质细胞增殖活性,成骨活性,免疫原性低,自身调节极其敏感,提取制作工艺简单等众多优点。 目的：体外观察成骨生长肽对大鼠颅盖骨来源成骨细胞在钛金属表面增殖分化的影响。 方法：将体外培养的新生SD大鼠颅盖骨成骨细胞以5×10⁷ L^-1细胞浓度接种于6孔板中的纯钛试件表面,分别加入0(空白对照),10^-10,10^-9,10^-8,10^-7 mol/L的成骨生长肽,干预1,3,5,7,9 d后应用MTT法检测纯钛试件表面成骨细胞的增殖活性,应用酶联免疫法检测成骨细胞内碱性磷酸酶活性。 结果与结论：与空白对照组比较,各浓度成骨生长肽组纯钛试件表面成骨细胞增殖活跃(P < 0.05),且最佳作用浓度为10^-9 mol/L(P < 0.05);各浓度成骨生长肽组细胞内碱性磷酸酶活性增强(P < 0.05),且最佳作用浓度为10^-8 mol/L (P < 0.05)。表明成骨生长肽可促进钛片表面成骨细胞的增殖活性,增强细胞内碱性磷酸酶活性。     

重组人骨形态发生蛋白2壳聚糖纳米微球的制备及体外细胞毒性

背景：通过各种微球负载骨生长因子使骨形态发生蛋白达到缓释效果逐渐成为研究热点,但关于载药壳聚糖纳米微球的生物相容性特别是细胞毒性的报道较少。 目的：对重组人骨形态发生蛋白2壳聚糖纳米微球进行细胞毒性检测,评估应用壳聚糖纳米微球作为重组人骨形态发生蛋白2缓释载体的生物安全性。 方法：通过离子交联法制备空白壳聚糖纳米微球,应用透视电镜观察微球的形态,激光粒径分析其粒径分布;通过重组人骨形态发生蛋白2壳聚糖纳米微球体外细胞毒性试验评估微球的生物安全性。 结果与结论：离子交联法制备的壳聚糖微球,球形规整,分散均匀,微球平均粒径为230 nm,分布较集中。载药及空白微球的反应分级为0或1级,均为合格。提示,离子交联法制备可成功制备出负载重组人骨形态发生蛋2的纳米微球,且微球细胞毒性检测合格,为进一步的骨组织工程研究提供理论实验基础。     

透明带3多肽-三甲基壳聚糖微球的制备及其在卵巢早衰中的应用

背景：透明带3多肽诱导口服耐受可预防及治疗自身免疫性卵巢早衰,但直接应用透明带3多肽治疗效果不十分理想,因此选择合适的药物载体系统成为进一步研究的基础。 目的：制备透明带3多肽-三甲基壳聚糖微球,观察其在卵巢早衰中的作用。 方法：采用离子交联法制备透明带3多肽-三甲基壳聚糖微球,观察微球形态,检测微球粒径、包封率、载药率及体外释放速度。分别以透明带3多肽-三甲基壳聚糖微球、磷酸盐缓冲液、透明带3多肽、三甲基壳聚糖灌胃治疗卵巢早衰小鼠。 结果与结论：透明带3多肽-三甲基壳聚糖微球形态较规则,平均粒径280.5 nm,包封率为69.20%,载药率为14.83%,随时间的延长,微球中透明带3多肽的体外释放率逐渐增加,无突释现象。透明带3多肽-三甲基壳聚糖微球组卵巢早衰小鼠外周血中抗透明带3多肽抗体阳性率明显低于其他3组(P < 0.05),表明透明带3多肽-三甲基壳聚糖微球治疗可明显减低卵巢早衰小鼠血清中抗透明带3多肽抗体阳性率。     

异硫氰酸荧光素标记的神经生长因子缓释微球的制备及评价

目的 探讨异硫氰酸荧光素(FITC)标记的神经生长因子缓释微球的制备,并对其进行体内外评价.方法 采用水-油-水的双乳化技术制备FITC标记的神经生长因子缓释微球.利用扫描电镜和荧光显微镜对其形态特征进行观察,并对其体内外释放情况进行研究.结果 制备的FITC标记的神经生长因子缓释微球包封率和载药量分别为(97.9±8.9)%和(4.90±0.56)%.扫描电镜结果显示所制备的微球呈圆形、形态规整、粒径分布较均匀.荧光显微镜结果显示所包载的蛋白类药物在微球内旱随机分布.缓释微球体外持续释放5周后,有73%的蛋白释放出来;荧光示踪显示在体内能够持续释放达5周以上.结论 采用水-油-水的双乳化技术制备的缓释微球可以将生物大分子药物如神经生长因子成功运载到脑内.     

Preparation,characterization and in vitro release of gentamicin from coralline hydroxyapatite-gelatin composite microspheres

Composite microspheres have been prepared from bioactive ceramics such as coralline hydroxyapatite [CHA, Ca10(PO4)6(OH)2] granules, a biodegradable polymer, gelatin and an antibiotic, gentamicin. In our earlier work, we have shown a gentamicin release from CHA granules--chitosan composite microspheres. In the present investigation, an attempt was made to prepare the composite microspheres containing coralline hydroxyapatite and gelatin (CHA-G), which were prepared by the dispersion polymerization technique and the gentamicin was incorporated by the absorption method. The crystal structure of the composite microspheres was analyzed using X-ray powder diffractometer. The Fourier transformed infrared spectrum clearly indicated the presence of amide and hydroxyl groups in the composite microspheres. Scanning electron micrographs and optical micrographs show that the composite microspheres are spherical in shape and porous in nature. The particle size of composite microspheres was analyzed and the average size was found to be 16 microm. The thermal behavior of composite microspheres was studied using thermogravimetric analysis and differential scanning calorimetric analysis. The cumulative in vitro release profile of gentamicin from composite microspheres showed near zero order patterns.     

In vitro and in vivo release of nerve growth factor from biodegradable poly-lactic-co-glycolic-acid microspheres

Regeneration of peripheral nerves after injury is suboptimal. We now report the long term delivery of nerve growth factor (NGF) by biodegradable poly-lactic-co-glycolic acid (PLGA) microspheres in vitro and in vivo. Lactic to glycolic acid ratios of 50:50 and 85:15 were fabricated using the double emulsion solvent, evaporation technique. Three different inherent viscosities (0.1 dL g(-1) : 1A, 0.4 dL g(-1) : 4A, 0.7 dL g(-1) : 7A) were analyzed. In vitro, release of NGF for 23 days was measured. Electron microscopy demonstrated intact spheres for at least 7 days (50:50 1A), 14 days (50:50 4A), or 35 days (50:50 7A and 85:15 7A). In vitro release kinetics was characterized by burst release, followed by release of NGF at a rate of 0.6-1.6% a day. Release curves for 50:50 1A and 85:15 7A differed significantly from other compositions (p < 0.01). In vivo, release was characterized by a novel radionuclide tracking assay. Release rates varied from 0.9 to 2.2% per day with linear kinetics. All but the 85:15 type of spheres showed different release profiles in vivo compared to in vitro conditions. On the basis of the surface morphology and release profiles, we found microspheres fabricated from 50:50 4A PLGA to be best suited for the use in a rat sciatic nerve injury model.     

成骨生长肽羧基端5肽衍生物G48A和阿仑膦酸钠的序贯治疗对去卵巢大鼠的影响

目的 探讨成骨生长肽羧基端5肽衍生物G48A与阿仑膦酸钠（Alen）的序贯治疗对去卵巢（OVX）大鼠离体骨密度和生物力学的影响。 方法 将3月龄雌性SD大鼠75只随机分7组,除假手术组（S组）外均行OVX术,1周后G48A1、G48A2、G48A3组分别以5-5-5d、10-10-5d、14-14-7d为周期交替给予G48A-（Alen）-间歇进行预防治疗;NADFR组每日联合予G48A和Alen;ALEN组每日予Alen;余OVX组和S组每日予安慰剂。术后13周处死,分离左股骨及1~4腰椎行骨密度（BMD）检测,右股骨行三点弯曲实验,第5腰椎行腰椎压缩实验。结果 与S组比较,OVX组体重增加, BMD明显降低,腰椎最大载荷、比例极限、强度极限和弹性模量以及股骨的弯曲能量明显减低;经过G48A1、2、3组及NADFR组预防性治疗各项指标绝大多数有改善趋势,其中腰椎和股骨BMD、腰椎弹性载荷以及股骨的弯曲弹性模量和弯曲刚性系数均较OVX组有显著提高。结论G48A与阿仑膦酸钠的序贯治疗可以改善去卵巢大鼠的骨丢失,增加骨密度,提高骨力学性能。     

Preparation of porous bioactive ceramic microspheres and in vitro osteoblastic culturing for tissue engineering application

Microparticulates are useful for directly filling defective tissues as well as for delivering cells and bioactive molecules in regenerative medicine. This paper reports on the production of bioactive ceramic microspheres with an interconnected macropore structure. The sol–gel derived calcium silicate powder was homogenized with an oligomeric Camphene melt, which was used as a novel porogen, and spherical-shaped microparticulates were obtained by an oil-in-water emulsion method. A porous structure was generated through the sublimation of Camphene within the calcium silicate–Camphene solidified blend under ambient conditions. The microspheres retained the crystalline phase of apatite and wollastonite during heat treatment and induced calcium phosphate precipitation under a body-simulating medium, showing the characteristics of bone-bioactive materials. Osteoblastic cells were observed to anchor to and spread well over the surface of the porous microspheres, and further to proliferate actively with culturing time. The bioactive and porous microspheres developed are considered potentially useful in the regeneration of hard tissues as a matrix for tissue engineering as well as a direct filling material.     

Preparation,characterization, and in vitro release of gentamicin from coralline hydroxyapatite-alginate composite microspheres

In this work, composite microspheres were prepared from bioactive ceramics such as coralline hydroxyapatite [Ca(10)(PO(4))(6)(OH)(2)] granules, a biodegradable polymer, sodium alginate, and an antibiotic, gentamicin. Previously, we have shown a gentamicin release from coralline hydroxyapatite granules-chitosan composite microspheres. In the present investigation, we attempted to prepare composite microspheres containing coralline hydroxyapatite granules and sodium alginate by the dispersion polymerization technique with gentamicin incorporated by absorption method. The crystal structure of the composite microspheres was analyzed using X-ray powder diffractometer. Fourier transform infrared spectra clearly indicated the presence of per-acid of sodium alginate, phosphate, and hydroxyl groups in the composite microspheres. Scanning electron micrographs and optical micrographs showed that the composite microspheres were spherical in shape and porous in nature. The particle size of composite microspheres was analyzed, and the average size was found to be 15 microns. The thermal behavior of composite microspheres was studied using thermogravimetric analysis and differential scanning calorimetric analysis. The cumulative in vitro release profile of gentamicin from composite microspheres showed near zero order patterns.     

Dual growth factor-immobilized microspheres for tissue reinnervation: in vitro and preliminary in vivo studies

Growth factors (GFs) (basic fibroblast growth factor (bFGF) and/or nerve growth factor (NGF))-immobilized polycaprolactone (PCL)/Pluronic F127 microspheres were prepared using an isolated particulate-melting method and the sequential binding of heparin and GFs onto the microspheres. The GFs immobilized on the microspheres were released in a sustained manner over 28 days, regardless of GF type. From the in vitro culture of muscle-derived stem cells, it was observed that the NGF-immobilized microspheres induced more neurogenic differentiation than the bFGF-immobilized microspheres, as evidenced by a quantitative real-time polymerase chain reaction using specific neurogenic markers (Nestin, GFAP, β-tubulin, and MAP2) and Western blot (Nestin and β-tubulin) analyses. The dual bFGF/NGF-immobilized microspheres showed better neurogenic differentiation than the microspheres immobilized with single bFGF or NGF. From the preliminary animal study, the dual bFGF/NGF-immobilized microsphere group also showed effective nerve regeneration, as evaluated by immunocytochemistry using a marker – β-tubulin. The dual bFGF/NGF-immobilized PCL/Pluronic F127 microspheres may be a promising candidate for nerve regeneration in certain target tissues (i.e. muscles) leading to sufficient reinnervation.     

Preparation, structure, and in vitro chemical durability of yttrium phosphate microspheres for intra-arterial radiotherapy

Chemically durable microspheres containing yttrium and/or phosphorus are useful for intra-arterial radiotherapy. In this study, we attempted to prepare yttrium phosphate (YPO?) microspheres with high chemical durability. YPO? microspheres with smooth surfaces and diameters of around 25 μm were successfully obtained when gelatin droplets containing yttrium and phosphate ions were cooled and solidified in a water-in-oil emulsion and then heat-treated at 1100°C. The chemical durability of the heat-treated microspheres in a simulated body fluid at pH = 6 and 7 was high enough for clinical application of intra-arterial radiotherapy.     

幽门螺杆菌全菌蛋白抗原壳聚糖微球体外释放特性

背景：不同方法制备出的幽门螺杆菌全菌蛋白抗原壳聚糖微球,其包裹率和控释效果也不同。 目的：探讨幽门螺杆菌全菌蛋白抗原壳聚糖微球的最佳制备方案,观察其体外释放特性。 方法：使用Berthold沉淀法制备壳聚糖微球,筛选最佳制备方案;使用扫描电镜及粒径分析仪观察壳聚糖微球的形态及粒径分布;冻干后的壳聚糖微球包裹幽门螺杆菌全菌蛋白抗原,使用BCA蛋白定量试剂盒测量分析微球的抗原包裹率、包裹量及释放率。 结果与结论：从32种壳聚糖微球制备方案中筛选出了以海得贝壳聚糖为原料、冰乙酸的浓度为1%、硫酸钠为沉淀剂、pH值为5.0、不进行超声处理方案为最佳制备方案,扫描电镜示微球光滑圆整、致密,粒径分布在1.0~5.0 μm;抗原包裹率为79.92%,包裹量为16.47%;体外释放实验表明,总抗原释放率为20.39%,呈缓慢释放状态。     

Recombinant growth/differentiation factor-5 stimulates osteogenic differentiation of fat-derived stromal cells in vitro

Fat-derived stromal cells can differentiate into various skeletal tissues. Currently the mechanism that determines whether stromal cells differentiate into osteoblasts is unclear and the role of growth/differentiation factor (GDF)-5 in differentiation of fat-derived stromal cells is not fully understood. It appears that the differentiation of stromal cells is greatly enhanced by GDF-5 that plays a role in a variety of musculoskeletal processes such as joint formation, tendon maintenance, and bone formation. Our study showed that GDF-5 promotes the differentiation of rat fat-derived stromal cells into osteogenic lineages in vitro. Furthermore, these findings were confirmed by histology, biochemical assay for alkaline phosphatase activity, and analysis of gene expression. The ability to preferentially stimulate fat-derived stromal cells down the osteogenic pathway holds significance in a variety of clinical scenarios.